HomeCompareSSMFF vs ABBV

SSMFF vs ABBV: Dividend Comparison 2026

SSMFF yields 13.13% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $54.9K in total portfolio value· pulled ahead in Year 6
10 years
SSMFF
SSMFF
● Live price
13.13%
Share price
$15.23
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.5K
Annual income
$2,970.58
Full SSMFF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SSMFF vs ABBV

📍 ABBV pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSSMFFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SSMFF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SSMFF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SSMFF
Annual income on $10K today (after 15% tax)
$1,116.22/yr
After 10yr DRIP, annual income (after tax)
$2,524.99/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $18,531.01/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SSMFF + ABBV for your $10,000?

SSMFF: 50%ABBV: 50%
100% ABBV50/50100% SSMFF
Portfolio after 10yr
$74.9K
Annual income
$13,871.17/yr
Blended yield
18.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SSMFF
No analyst data
Altman Z
3.4
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SSMFF buys
0
ABBV buys
0
No recent congressional trades found for SSMFF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSSMFFABBV
Forward yield13.13%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$47.5K$102.3K
Annual income after 10y$2,970.58$24,771.77
Total dividends collected$21.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SSMFF vs ABBV ($10,000, DRIP)

YearSSMFF PortfolioSSMFF Income/yrABBV PortfolioABBV Income/yrGap
1$12,013$1,313.20$11,550$430.00+$463.00SSMFF
2$14,328$1,474.36$13,472$627.96+$856.00SSMFF
3$16,975$1,643.47$15,906$926.08+$1.1KSSMFF
4$19,983$1,819.65$19,071$1,382.55+$912.00SSMFF
5$23,384$2,001.95$23,302$2,095.81+$82.00SSMFF
6← crossover$27,210$2,189.39$29,150$3,237.93$1.9KABBV
7$31,495$2,380.97$37,536$5,121.41$6.0KABBV
8$36,276$2,575.68$50,079$8,338.38$13.8KABBV
9$41,588$2,772.54$69,753$14,065.80$28.2KABBV
10$47,469$2,970.58$102,337$24,771.77$54.9KABBV

SSMFF vs ABBV: Complete Analysis 2026

SSMFFStock

SFC Energy AG develops, produces, and distributes systems and solutions for stationary and mobile off-grid power supply based on hydrogen and direct methanol fuel cells worldwide. The company operates in two segments, Clean Energy and Clean Power Management. It offers EFOY Hydrogen 2.5 fuel cells for higher power ranges; EFOY Pro fuel cells for on-board power supply in vehicles, as well as off-grid power supply, such as monitoring systems, measuring stations, and oil and gas applications; EFOY fuel cells, which ensures automatic recharge of the batteries; SFC EMILY for military and security applications; SFC JENNY, a portable fuel cell for military applications; and SFC Power Manager 3G, a portable power distributor and battery charger that enables the soldiers to use various energy sources available in the field, such as hybrid batteries, solar panels, and vehicle power and fuel cells to power devices or charge batteries. The company also provides EFOY ProCube, a mobile and maintenance-free solution for off-grid power supplies; EFOY ProEnergyBox, an off-grid energy solution for weather conditions; EFOY ProEnergyCase, a portable and maintenance-free solution for grid-independent power supplies; EFOY ProCabinet, an insulated outdoor energy solution for remote off-grid power supply; EFOY ProTrailer, a trailer-based energy solution; drives and motor solutions; SCADA and telemetry solutions; and coils and linear drives. In addition, it offers accessories and spare parts, such as fuel cartridges; and mechanical, electronic, and electrical instruments to monitor and control production and logistics processes. The company was formerly known as SFC Smart Fuel Cell AG and changed its name to SFC Energy AG in July 2010. SFC Energy AG was founded in 2000 and is headquartered in Brunnthal, Germany.

Full SSMFF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SSMFF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SSMFF vs SCHDSSMFF vs JEPISSMFF vs OSSMFF vs KOSSMFF vs MAINSSMFF vs JNJSSMFF vs MRKSSMFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.